Eisenwort, Gregor http://orcid.org/0000-0003-2735-4645
Sadovnik, Irina
Schwaab, Juliana
Jawhar, Mohamad
Keller, Alexandra
Stefanzl, Gabriele
Berger, Daniela
Blatt, Katharina
Hoermann, Gregor
Bilban, Martin
Willmann, Michael
Winding, Christiana
Sperr, Wolfgang R.
Arock, Michel
Rülicke, Thomas http://orcid.org/0000-0002-2121-9496
Reiter, Andreas
Valent, Peter
Funding for this research was provided by:
Austrian Science Fund (SFB F47)
Article History
Received: 25 September 2018
Revised: 17 March 2019
Accepted: 18 March 2019
First Online: 5 April 2019
Compliance with ethical standards
:
: PV received a research grant from Novartis, from Blueprint, and from Deciphera, and received honoraria from Novartis, Celgene, Pfizer and Deciphera. PV and AR served as a Consultant in the global Novartis trial examining the effects of midostaurin in advanced SM. WRS received honoraria from Novartis and Celgene. MA received honoraria from Deciphera, Novartis and Roche Diagnostics, and a research grant from Agensys Inc., Blueprint Medicines and Deciphera. AR received a research grant from Novartis, honoraria from Novartis and BMS, and served in advisory boards organized by Deciphera, Blueprint and Baxalta/Shire. GH received honoraria from Novartis. The other authors declare that they have no conflict of interest.